Samsung Bioepis acquired domestic approval for Brenzys™

Published: 2015-09-09 14:04:21

Updated: 2015-09-09 14:04:21

Samsung Bioepis and MSD Korea announced the Samsung Bioepis’s first biosimilar, Brenzys™, has been approved by the Ministry of Food and Drug Safety(MFDS) on the 7^th.

The MFDS approved Brenzys™ to be used for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis(ankylosing spondylitis, axial spondyloarthritis that is not detected by radiation) and psoriasis; thus, sales of Brenzys™...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.